JP2024543413A5 - - Google Patents

Info

Publication number
JP2024543413A5
JP2024543413A5 JP2024527604A JP2024527604A JP2024543413A5 JP 2024543413 A5 JP2024543413 A5 JP 2024543413A5 JP 2024527604 A JP2024527604 A JP 2024527604A JP 2024527604 A JP2024527604 A JP 2024527604A JP 2024543413 A5 JP2024543413 A5 JP 2024543413A5
Authority
JP
Japan
Prior art keywords
compound according
ray powder
pharmaceutical composition
diffraction pattern
powder diffraction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024527604A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024543413A (ja
Filing date
Publication date
Priority claimed from EP21207942.0A external-priority patent/EP4180428A1/en
Application filed filed Critical
Publication of JP2024543413A publication Critical patent/JP2024543413A/ja
Publication of JP2024543413A5 publication Critical patent/JP2024543413A5/ja
Pending legal-status Critical Current

Links

JP2024527604A 2021-11-12 2022-11-11 結晶性イミダゾ[4,5-b]ピリジン化合物、医薬組成物、及び医学的状態を治療する際のそれらの使用 Pending JP2024543413A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21207942.0 2021-11-12
EP21207942.0A EP4180428A1 (en) 2021-11-12 2021-11-12 Crystalline imidazo[4,5-b]pyridine compound, pharmaceutical compositions, and their use in treating medical conditions
PCT/US2022/049695 WO2023086564A1 (en) 2021-11-12 2022-11-11 Crystalline imidazo[4,5-b]pyridine compound, pharmaceutical compositions, and their use in treating medical conditions

Publications (2)

Publication Number Publication Date
JP2024543413A JP2024543413A (ja) 2024-11-21
JP2024543413A5 true JP2024543413A5 (cg-RX-API-DMAC10.html) 2025-11-18

Family

ID=78617277

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024527604A Pending JP2024543413A (ja) 2021-11-12 2022-11-11 結晶性イミダゾ[4,5-b]ピリジン化合物、医薬組成物、及び医学的状態を治療する際のそれらの使用

Country Status (10)

Country Link
US (3) US11814383B2 (cg-RX-API-DMAC10.html)
EP (2) EP4180428A1 (cg-RX-API-DMAC10.html)
JP (1) JP2024543413A (cg-RX-API-DMAC10.html)
CN (1) CN118843624A (cg-RX-API-DMAC10.html)
AU (1) AU2022387516A1 (cg-RX-API-DMAC10.html)
CA (1) CA3237156A1 (cg-RX-API-DMAC10.html)
IL (1) IL312625A (cg-RX-API-DMAC10.html)
MX (1) MX2024005766A (cg-RX-API-DMAC10.html)
TW (1) TW202334143A (cg-RX-API-DMAC10.html)
WO (1) WO2023086564A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9067914B1 (en) * 2013-12-10 2015-06-30 Genzyme Corporation Tropomyosin-related kinase (TRK) inhibitors
EP4180428A1 (en) 2021-11-12 2023-05-17 Genzyme Corporation Crystalline imidazo[4,5-b]pyridine compound, pharmaceutical compositions, and their use in treating medical conditions
AU2024273547A1 (en) * 2023-05-17 2025-12-04 Centrexion Therapeutics Corporation PARTICLES OF IMIDAZO [4,5-b] PYRIDINE COMPOUND, PHARMACEUTICAL COMPOSITIONS, AND THEIR USE IN TREATING MEDICAL CONDITIONS

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL150524A0 (en) * 2000-01-07 2003-02-12 Transform Pharmaceuticals Inc High-throughput formation, identification, and analysis of diverse solid-forms
US9067914B1 (en) 2013-12-10 2015-06-30 Genzyme Corporation Tropomyosin-related kinase (TRK) inhibitors
MA40698A3 (fr) 2014-12-18 2020-01-31 Genzyme Corp Formulations pharmaceutiques d'inhibiteurs de kinase associée à la tropomyosine (trk)
CA3080157A1 (en) 2017-10-26 2019-05-02 Array Biopharma Inc. Formulations of a macrocyclic trk kinase inhibitor
EP3773725A1 (en) 2018-03-29 2021-02-17 Loxo Oncology Inc. Treatment of trk-associated cancers
MX2021001957A (es) 2018-08-22 2021-07-15 Cullgen Shanghai Inc Compuestos de degradacion y metodos de uso del receptor de tropomiosina quinasa (trk).
BR112022016901A2 (pt) * 2020-02-26 2022-12-06 Cullgen Shanghai Inc Compostos de degradação do receptor de tropomiosina quinase (trk) e métodos de uso
EP4180428A1 (en) 2021-11-12 2023-05-17 Genzyme Corporation Crystalline imidazo[4,5-b]pyridine compound, pharmaceutical compositions, and their use in treating medical conditions

Similar Documents

Publication Publication Date Title
KR102425226B1 (ko) Jak 저해제를 포함하는 제약 조성물
JP5371790B2 (ja) 睡眠および認知に関するうつ病における残存症状の治療のための組み合わされたセロトニン再取り込み、5−ht3および5−ht1a活性を有する化合物としての1−[2−(2,4−ジメチルフェニルスルファニル)フェニル]ピペラジン
TWI359128B (en) New crystalline form v of agomelatine, a process f
HRP20231533T1 (hr) Kristalni oblici od (s)-1-(4-fluorofenil)-1-(2-(4-(6-(1-metil-1h-pirazol-4-il)pirolo[2,1-f][1,2,4 ]triazin-4-il)piperazinil)-pirimidin-5-il)etan-1-amina i postupci priprave
EA031116B1 (ru) КРИСТАЛЛИЧЕСКИЕ ПОЛИМОРФНЫЕ ФОРМЫ {3-[5-(4-ХЛОРФЕНИЛ)-1H-ПИРРОЛО[2,3-b]ПИРИДИН-3-КАРБОНИЛ]-2,4-ДИФТОРФЕНИЛ}АМИДА ПРОПАН-1-СУЛЬФОНОВОЙ КИСЛОТЫ
US20160143909A1 (en) Pharmaceutical composition
US9669003B2 (en) Use of flavone and flavanone derivatives in preparation of sedative and hypnotic drugs
JP2013014584A (ja) アゴメラチンの新規な共結晶、その調製のための方法及びそれを含む医薬組成物
JP3726291B2 (ja) 安定な結晶構造を有するベンゾオキサジン化合物およびその製造法
EP3819298B1 (en) Compound having trka inhibitory activity and pharmaceutical composition, for preventing or alleviating pain, containing same as active ingredient
JP2014506602A5 (cg-RX-API-DMAC10.html)
JP2026041824A (ja) テガビビントの結晶形態、調製方法、及びその使用
CA3001850A1 (en) Solabegron zwitterion and uses thereof
TW202334143A (zh) 結晶咪唑并[4,5-b]吡啶化合物、醫藥組合物及彼等治療醫學症狀之用途
WO2024024961A1 (ja) 2(1h)-ピリジンイミン誘導体
JP2025506783A5 (cg-RX-API-DMAC10.html)
JP2004504390A (ja) (r)−n−[5−メチル−8−(4−メチルピペラジン−1−イル)−1,2,3,4−テトラヒドロ−2−ナフチル]−4−モルホリノベンズアミドの新規な形態
JP2002505254A (ja) パロキセチン塩
TW200838537A (en) Substituted quinazolines
TWI900603B (zh) 八氫噻吩并喹啉化合物之琥珀酸鹽及其結晶
EP1163241B1 (en) Zolpidem salts
KR20150054860A (ko) 포스파티딜이노시톨 3-키나아제 억제제의 정제 제형
KR20240056457A (ko) 마크로사이클릭 아졸로피리딘
CN113795492A (zh) 无定形pi3k抑制剂和包含其的药物组合物
JP2016522224A (ja) ピロロキノリンキノンリチウム塩の結晶体及び調製方法と応用